What essential topics should be covered in an introductory 'Basics of Paraproteinemia' section for a presentation?

Basics of Paraproteinemia

Definition and Pathophysiology

Paraproteinemia is defined by the presence of a monoclonal immunoglobulin (M-protein or paraprotein) in blood or urine, produced by a clonal population of B-cells or plasma cells. 1, 2 This M-protein typically consists of intact immunoglobulin molecules (IgG, IgA, IgM, or rarely IgD) or their components (heavy chains, light chains, or both) 3, 4.

The underlying mechanism involves:

• Clonal proliferation: A single clone of plasma cells or B-lymphocytes produces identical immunoglobulin molecules
• Bone marrow involvement: Neoplastic B-lymphocytes originate from follicular germinal centers and migrate to bone marrow, where they interact with stromal cells 3
• Cytokine dysregulation: Interleukin-6 (IL-6) serves as the crucial growth factor, promoting proliferation and inhibiting apoptosis 3

Clinical Spectrum

Paraproteinemias exist along a continuum from benign to malignant conditions 5, 1:

1. Monoclonal Gammopathy of Undetermined Significance (MGUS)

• Serum M-protein <30 g/L (or <3 g/dL)
• Bone marrow clonal plasma cells <10%
• Absence of end-organ damage (no CRAB criteria)
• Progression risk: 1% per year to myeloma 5, 1, 6

2. Smoldering (Asymptomatic) Multiple Myeloma (SMM)

• Serum M-protein ≥30 g/L (or ≥3 g/dL) and/or bone marrow plasma cells ≥10%
• No symptoms or end-organ damage
• Median time to progression: 2-3 years 5, 1

3. Symptomatic Multiple Myeloma

• Bone marrow clonal plasma cells ≥10%
• Presence of M-protein (except non-secretory myeloma)
• Evidence of end-organ damage attributable to plasma cell disorder 1, 2

CRAB Criteria (End-Organ Damage)

The presence of any CRAB feature distinguishes symptomatic myeloma from asymptomatic conditions 5, 1, 2:

• Calcium elevation: Serum calcium ≥11.5 mg/dL
• Renal insufficiency: Serum creatinine >1.73 mmol/L or creatinine clearance <40 mL/min
• Anemia: Hemoglobin <10 g/dL or >2 g/dL below lower limit of normal
• Bone lesions: Lytic lesions, severe osteopenia, or pathologic fractures

Epidemiology

• Incidence: 3.2% in individuals >50 years; 6.0/100,000 per year in Europe 4, 6
• Age: Median age at diagnosis 65-70 years; <10% diagnosed before age 40 5, 4, 3
• Demographics: Twice as common in males; higher in Black populations 3

Diagnostic Evaluation

Essential Laboratory Tests 2, 4:

Serum studies:

• Serum protein electrophoresis (SPEP) and immunofixation (SIFE)
• Quantitative immunoglobulins (IgG, IgA, IgM)
• Serum free light chain (FLC) assay with kappa/lambda ratio
• Beta-2 microglobulin, albumin, LDH, calcium

Urine studies:

• 24-hour urine protein electrophoresis (UPEP) and immunofixation (UIFE)

Bone marrow evaluation:

• Aspiration and biopsy to quantify clonal plasma cells (≥10% required for myeloma diagnosis)
• Immunohistochemistry or flow cytometry to confirm clonality (kappa vs lambda light chain restriction)
• Cytogenetic studies: FISH analysis for high-risk abnormalities (del 17p, t(4;14), t(14;16)) 2, 3

Imaging 4:

• Full skeletal survey (X-ray) to detect lytic lesions
• MRI or PET/CT for equivocal cases or suspected cord compression

Clinical Pitfalls

Critical diagnostic caveats 5:

• Elderly patients may have concomitant conditions mimicking myeloma:
  • Mild creatinine elevation from diabetes/hypertension (not myeloma kidney)
  • Anemia from B12/folate deficiency or myelodysplasia (not myeloma-related)
  • Osteoporosis with gradual progression (not acute lytic disease)
  • Hyperparathyroidism causing hypercalcemia (check PTH levels)

M-Protein Related Complications

Beyond malignant transformation, paraproteins can cause direct organ damage 7:

• AL amyloidosis: Misfolded light chains deposit as amyloid fibrils (heart, kidney, liver, nerves)
• Cryoglobulinemia: Temperature-dependent precipitation causing Raynaud's, vasculitis, neuropathy
• Hyperviscosity syndrome: Particularly with IgM paraproteins
• Peripheral neuropathy: Especially anti-MAG antibodies in IgM MGUS 7, 8
• Renal disease: Cast nephropathy, light chain deposition disease 9

Prognostic Factors

MGUS Risk Stratification 1:

Three factors predict progression:

• M-protein ≥15 g/L
• Non-IgG subtype
• Abnormal FLC ratio

SMM Risk Stratification 5, 1:

Three factors predict progression:

• M-protein ≥30 g/L
• Bone marrow plasma cells ≥10%
• Abnormal FLC ratio

Patients with all three factors have 76% 5-year progression rate vs 25% with one factor.

Multiple Myeloma Staging:

• International Staging System (ISS): Based on beta-2 microglobulin and albumin 4
• Revised ISS (R-ISS): Incorporates high-risk cytogenetics and LDH 3, 2

Monitoring Recommendations

MGUS 1:

• Low-risk: Repeat evaluation at 6 months, then every 2-3 years if stable
• High-risk: Annual follow-up indefinitely

SMM 5, 1:

• Every 3-4 months for first year
• Every 4-6 months for second year
• Every 6-12 months thereafter if stable